Amended Current Report Filing (8-k/a)
October 27 2020 - 8:54AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
June
23, 2020
Date
of Report
(Date
of earliest event reported)
BOQI
International Medical Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-50155
|
|
02-0563302
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification No.)
|
Room
3601, Building A, Harbour View Place, No. 2 Wuwu Road,
Zhongshan District, Dalian, Liaoning Province, P. R. China, 116000
|
(Address
of principal executive offices and zip code)
|
(8604)
1182209211
|
(Registrant’s
telephone number, including area code)
|
Not
Applicable
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common stock, $0.001
par value
|
|
BIMI
|
|
The NASDAQ Capital
Market
|
2.01
Completion of Acquisition or Disposition of Assets
This Amendment to our Current Report on Form
8-K filed on April 1, 2020 (this “Amendment”) is being filed by BOQI International Medical Inc. (the “Company”)
in connection with the completion of the sale of the Company’s legacy energy saving enhancement business conducted through
NF Energy Saving Investment Limited and its subsidiaries on June 23, 2020. This Amendment is being filed to provide the pro forma
financial information required by Item 9.01 (b) of Form 8-K.
Item
9.01 Financial Statements and Exhibits
(b)
Pro Forma Financial Information
The Unaudited Pro Forma Condensed Consolidated
Balance Sheet as of June 30, 2020 and Unaudited Pro Forma Condensed Statements of Operations for the Six Months Ended June 30,
2020, are filed as Exhibit 99.2 to this Current Report on Form 8-K/A.
(c)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: October 27,
2020
|
|
|
|
|
|
BOQI International Medical Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Tiewei Song
|
|
|
Tiewei Song
|
|
|
Chief Executive Officer
|
2
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Sep 2023 to Sep 2024